Bioequivalence and Bioavailability Forum 22:07 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Pathway for Softgel vs Tablet Comparison [Design Issues]

posted by Obinoscopy - Nigeria, 2018-05-15 19:04  - Posting: # 18764
Views: 684

Dear bebac_fan,

» I think this would need to go through a NDA/505(b)(2) pathway rather than an ANDA.
»

I share the same view with you on this.

However I have a case where a BE study was conducted comparing Metronidazole tablet (Reference) with Metronidazole soft gel (test). Both were IR. Is this acceptable?

Regards,

Scopy

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,935 posts in 4,039 threads, 1,287 registered users;
online 7 (1 registered, 6 guests [including 5 identified bots]).

There are no such things as applied sciences,
only applications of science.    Louis Pasteur

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed